Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raltegravir Potassium

FDA-approved product (tablet, oral), marketed as Isentress, Isentress Hd, Raltegravir Potassium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Raltegravir Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raltegravir Potassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-9.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raltegravir Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

    NCT01900015 · start 2014-02-03

    Registered record
    Registry ID
    NCT01900015
    Conditions
    HCV Coinfection; HIV Infection
    Interventions
    Raltegravir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02-03
    Completion
    2017-01-17
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Coinfection; HIV Infection
    InterventionRaltegravir; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated

  • Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

    NCT01679964 · start 2012-07

    Registered record
    Registry ID
    NCT01679964
    Conditions
    HIV Infection; Adverse Drug Reaction; Quality of Life
    Interventions
    Raltegravir switch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-02
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Adverse Drug Reaction; Quality of Life
    InterventionRaltegravir switch
    PhasePhase 4
    Registry statusCompleted

  • Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01533259 · start 2012-01

    Registered record
    Registry ID
    NCT01533259
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionStribild
    PhasePhase 3
    Registry statusCompleted

  • GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance

    NCT01381328 · start 2011-12

    Registered record
    Registry ID
    NCT01381328
    Conditions
    HIV-1 Infected Patients; Fold-change Resistance; Resistance Mutations
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-12
    Completion
    2013-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infected Patients; Fold-change Resistance; Resistance Mutations
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated

  • Effects of Intensive cART During Acute/Early HIV Infection

    NCT01154673 · start 2011-11

    Registered record
    Registry ID
    NCT01154673
    Conditions
    Acute HIV Infection
    Interventions
    raltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    Interventionraltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Levels of Raltegravir in the Female Genital Tissue

    NCT01327482 · start 2011-10

    Registered record
    Registry ID
    NCT01327482
    Conditions
    HIV
    Interventions
    Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-10
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRaltegravir
    PhaseNot applicable
    Registry statusCompleted

  • Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

    NCT00984152 · start 2011-06

    Registered record
    Registry ID
    NCT00984152
    Conditions
    HIV-1 Infections
    Interventions
    TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily; TDF/FTC + Efavirenz (Atripla) Once-Daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2011-06
    Completion
    2013-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infections
    InterventionTDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily; TDF/FTC + Efavirenz (Atripla) Once-Daily
    PhasePhase 3
    Registry statusWithdrawn

  • A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

    NCT01328041 · start 2011-05

    Registered record
    Registry ID
    NCT01328041
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-05
    Enrolment
    183

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventiondolutegravir
    PhasePhase 3
    Registry statusCompleted

  • Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

    NCT01294761 · start 2011-02

    Registered record
    Registry ID
    NCT01294761
    Conditions
    HIV Infections
    Interventions
    Raltegravir, Darunavir/r
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-02
    Completion
    2013-12
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir, Darunavir/r
    PhaseNot applicable
    Registry statusCompleted

  • Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

    NCT01189695 · start 2010-12

    Registered record
    Registry ID
    NCT01189695
    Conditions
    HIV; AIDS; Lopinavir; Treatment Failure
    Interventions
    Ritonavir-boosted lopinavir; optimized background regimens (OBRs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2013-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Lopinavir; Treatment Failure
    InterventionRitonavir-boosted lopinavir; optimized background regimens (OBRs)
    PhasePhase 4
    Registry statusCompleted

  • A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

    NCT01227824 · start 2010-10-19

    Registered record
    Registry ID
    NCT01227824
    Conditions
    Infection, Human Immunodeficiency Virus I
    Interventions
    GSK1349572 (dolutegravir); raltegravir; GSK1349572 Placebo; ABC/3TC; TDF/FTC; raltegravir Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-19
    Completion
    2016-12-27
    Enrolment
    828

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I
    InterventionGSK1349572 (dolutegravir); raltegravir; GSK1349572 Placebo; ABC/3TC +2 more
    PhasePhase 3
    Registry statusCompleted

  • Safety Study of Raltegravir in HIV/HCV Co-infected Patients

    NCT01225705 · start 2010-10

    Registered record
    Registry ID
    NCT01225705
    Conditions
    HIV; Hepatitis C
    Interventions
    raltegravir; Atazanavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2010-10
    Completion
    2012-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Hepatitis C
    Interventionraltegravir; Atazanavir/ritonavir
    PhasePhase 4
    Registry statusWithdrawn